ERIS Lifescience

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE406M01024
NSEID: ERIS
BSEID: 540596
View on NSE | View on BSE

INR

1,399.75

33 (2.41%)

BSENSE

Jun 12, 12:59 PM

BSE+NSE Vol: 32.79 k

{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,399.75",
    "chg": 33,
    "chgp": "2.41%",
    "dir": 1,
    "prev_price": "1,366.75",
    "mcapval": "19,395.96 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE406M01024",
    "curr_date": "Jun 12, 12:59 PM",
    "curr_time": "13:00 PM",
    "last_traded_at": "Jun 12, 12:59 PM IST",
    "bse_nse_vol": "32.79 k",
    "exc_status": "Active",
    "traded_date": "Jun 12, 2026",
    "traded_date_str": "2026 06 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Ltd Upgraded to Hold on Technical and Financial Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-upgraded-to-hold-on-technical-and-financial-improvements-4046067",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ERISLifescience_mojoScore_4046067.png",
        "date": "2026-06-11 08:26:53",
        "description": "ERIS Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite recent price softness, the company’s improving financial trends and stable quality parameters underpin this revised stance, signalling cautious optimism for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-4040211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ERISLifescience_technicaldot_4040211.png",
        "date": "2026-06-09 08:04:08",
        "description": "ERIS Lifesciences Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend, as reflected in recent indicator readings. Despite a modest day gain of 0.29%, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum indicators, suggesting cautious investor sentiment amid broader sector challenges."
      },
      {
        "title": "ERIS Lifesciences Downgraded to Sell Amid Technical Weakness and Valuation Shift",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-downgraded-to-sell-amid-technical-weakness-and-valuation-shift-4038232",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ERISLifescience_mojoScore_4038232.png",
        "date": "2026-06-08 08:17:31",
        "description": "ERIS Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 5 June 2026. This change reflects a combination of deteriorating technical indicators, a shift in valuation metrics, and mixed financial trends despite recent positive quarterly results. The company’s Mojo Score now stands at 47.0, signalling caution for investors amid a challenging market backdrop."
      },
      {
        "title": "ERIS Lifesciences Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-faces-bearish-momentum-amid-technical-downgrade-4037957",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ERISLifescience_technicaldot_4037957.png",
        "date": "2026-06-08 08:03:01",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bearish to a more pronounced bearish trend. The company’s stock price has declined modestly in recent sessions, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade to Sell."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-4037571",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ERISLifescience_valuationdot_4037571.png",
        "date": "2026-06-08 08:02:02",
        "description": "ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and presents a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector. Despite a modest day decline of 0.48%, the company’s valuation metrics and comparative analysis against peers and historical benchmarks offer valuable insights for investors navigating a complex market environment."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-changing-market-sentiment-4025473",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ERISLifescience_valuationdot_4025473.png",
        "date": "2026-06-01 08:06:33",
        "description": "ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving investor sentiment amid a volatile pharmaceutical sector. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the company’s price-to-earnings and price-to-book ratios now position it at a premium relative to historical averages and peer benchmarks."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-hold-4024229",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_mojoScore_4024229.png",
        "date": "2026-05-31 10:10:42",
        "description": "ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with an up-to-date view of its performance and outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-4009880",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_valuationdot_4009880.png",
        "date": "2026-05-25 08:01:23",
        "description": "ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, driven primarily by adjustments in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, marks a significant development for investors assessing the stock’s price attractiveness relative to its historical levels and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd’s Volatile Week: -2.15% Price Change Amid Strong Quarterly Upswing",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltds-volatile-week--215-price-change-amid-strong-quarterly-upswing-4008229",
        "imagepath": "",
        "date": "2026-05-23 13:03:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>18 May:</strong> Stock opens at Rs.1,340.30, down 2.45%</p>\n                    <p><strong>20 May:</strong> Intraday high of Rs.1,458 with 8.32% surge</p>\n                    <p><strong>21 May:</strong> Reports strong quarterly upswing with record profitability</p>\n                    <p><strong>22 May:</strong> Week closes at Rs.1,344.35, down 0.31% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,373.95</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,344.35</div><di..."
      }
    ],
    "total": 332,
    "sid": "1002771",
    "stock_news_url": "https://www.marketsmojo.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "caption": "Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD",
      "datetime": "08-Jun-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Imposition Of Fine By BSE Limited And National Stock Exchange Of India Limited",
      "datetime": "28-May-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "27-May-2026",
      "details": "As Attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>721%</strong> dividend, ex-date: 29 May 26",
          "dt": "2026-05-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

ERIS Lifesciences Ltd Upgraded to Hold on Technical and Financial Improvements

2026-06-11 08:26:53

ERIS Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite recent price softness, the company’s improving financial trends and stable quality parameters underpin this revised stance, signalling cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-06-09 08:04:08

ERIS Lifesciences Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend, as reflected in recent indicator readings. Despite a modest day gain of 0.29%, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum indicators, suggesting cautious investor sentiment amid broader sector challenges.

Read full news article

ERIS Lifesciences Downgraded to Sell Amid Technical Weakness and Valuation Shift

2026-06-08 08:17:31

ERIS Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 5 June 2026. This change reflects a combination of deteriorating technical indicators, a shift in valuation metrics, and mixed financial trends despite recent positive quarterly results. The company’s Mojo Score now stands at 47.0, signalling caution for investors amid a challenging market backdrop.

Read full news article

ERIS Lifesciences Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-06-08 08:03:01

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bearish to a more pronounced bearish trend. The company’s stock price has declined modestly in recent sessions, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade to Sell.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-06-08 08:02:02

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and presents a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector. Despite a modest day decline of 0.48%, the company’s valuation metrics and comparative analysis against peers and historical benchmarks offer valuable insights for investors navigating a complex market environment.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment

2026-06-01 08:06:33

ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving investor sentiment amid a volatile pharmaceutical sector. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the company’s price-to-earnings and price-to-book ratios now position it at a premium relative to historical averages and peer benchmarks.

Read full news article

ERIS Lifesciences Ltd is Rated Hold

2026-05-31 10:10:42

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with an up-to-date view of its performance and outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-05-25 08:01:23

ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, driven primarily by adjustments in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, marks a significant development for investors assessing the stock’s price attractiveness relative to its historical levels and peer group within the Pharmaceuticals & Biotechnology sector.